| pubmed-article:16603217 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16603217 | lifeskim:mentions | umls-concept:C0003451 | lld:lifeskim |
| pubmed-article:16603217 | lifeskim:mentions | umls-concept:C0282554 | lld:lifeskim |
| pubmed-article:16603217 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:16603217 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:16603217 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:16603217 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:16603217 | pubmed:dateCreated | 2006-7-3 | lld:pubmed |
| pubmed-article:16603217 | pubmed:abstractText | Antimicrobial peptides are a diverse family of small, mostly cationic polypeptides that kill bacteria, fungi and even some enveloped viruses, while chemokines are a group of mostly cationic small proteins that induce directed migration of leukocytes through interactions with a group of seven transmembrane G protein-coupled receptors. Recent studies have shown that antimicrobial peptides and chemokines have substantially overlapping functions. Thus, while some antimicrobial peptides are chemotactic for leukocytes, some chemokines can kill a wide range of bacteria and fungi. Here, we examined a possible direct antiviral activity of chemokines against an enveloped virus HSV-1. Among 22 human chemokines examined, chemokines such as MIP-1 alpha/CCL3, MIP-1 beta/CCL4 and RANTES/CCL5 showed a significant direct antiviral activity against HSV-1. It is intriguing that these chemokines are mostly known to be highly expressed by effector CD8+ T cells. The chemokines with a significant anti-HSV-1 activity commonly bound to HSV-1 virions via envelope glycoprotein gB. Electron microscopy revealed that the chemokines with a significant anti-HSV-1 activity were commonly capable of generating pores in the envelope of HSV-1. Thus, some chemokines have a significant direct antiviral activity against HSV-1 in vitro and may have a potential role in host defense against HSV-1 as a direct antiviral agent. | lld:pubmed |
| pubmed-article:16603217 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16603217 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603217 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16603217 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603217 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603217 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603217 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16603217 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:16603217 | pubmed:issn | 0042-6822 | lld:pubmed |
| pubmed-article:16603217 | pubmed:author | pubmed-author:TanS FSF | lld:pubmed |
| pubmed-article:16603217 | pubmed:author | pubmed-author:NakayamaTakas... | lld:pubmed |
| pubmed-article:16603217 | pubmed:author | pubmed-author:ShimomuraYosh... | lld:pubmed |
| pubmed-article:16603217 | pubmed:author | pubmed-author:YoshieOsamuO | lld:pubmed |
| pubmed-article:16603217 | pubmed:author | pubmed-author:HieshimaKunio... | lld:pubmed |
| pubmed-article:16603217 | pubmed:author | pubmed-author:SaitoTakuyaT | lld:pubmed |
| pubmed-article:16603217 | pubmed:author | pubmed-author:NagakuboDaisu... | lld:pubmed |
| pubmed-article:16603217 | pubmed:author | pubmed-author:ShibanoMichik... | lld:pubmed |
| pubmed-article:16603217 | pubmed:author | pubmed-author:ShiraneJumiJ | lld:pubmed |
| pubmed-article:16603217 | pubmed:author | pubmed-author:WatanabeMasay... | lld:pubmed |
| pubmed-article:16603217 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16603217 | pubmed:day | 5 | lld:pubmed |
| pubmed-article:16603217 | pubmed:volume | 350 | lld:pubmed |
| pubmed-article:16603217 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16603217 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16603217 | pubmed:pagination | 484-92 | lld:pubmed |
| pubmed-article:16603217 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16603217 | pubmed:meshHeading | pubmed-meshheading:16603217... | lld:pubmed |
| pubmed-article:16603217 | pubmed:meshHeading | pubmed-meshheading:16603217... | lld:pubmed |
| pubmed-article:16603217 | pubmed:meshHeading | pubmed-meshheading:16603217... | lld:pubmed |
| pubmed-article:16603217 | pubmed:meshHeading | pubmed-meshheading:16603217... | lld:pubmed |
| pubmed-article:16603217 | pubmed:meshHeading | pubmed-meshheading:16603217... | lld:pubmed |
| pubmed-article:16603217 | pubmed:meshHeading | pubmed-meshheading:16603217... | lld:pubmed |
| pubmed-article:16603217 | pubmed:meshHeading | pubmed-meshheading:16603217... | lld:pubmed |
| pubmed-article:16603217 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16603217 | pubmed:articleTitle | Novel antiviral activity of chemokines. | lld:pubmed |
| pubmed-article:16603217 | pubmed:affiliation | Department of Microbiology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. | lld:pubmed |
| pubmed-article:16603217 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16603217 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16603217 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16603217 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16603217 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16603217 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16603217 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16603217 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16603217 | lld:pubmed |
